Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 54 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

46%

25 trials in Phase 3/4

Results Transparency

0 of 48 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2

24(44.4%)

Phase 3

23(42.6%)

N/A

5(9.3%)

Phase 4

2(3.7%)

54Total

Phase 2(24)

Phase 3(23)

N/A(5)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (54)

Showing 20 of 54 trials

NCT07210164Not ApplicableRecruiting

Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study

Role: collaborator

NCT07179237Phase 2Recruiting

Efficacy of Carminal in Helicobacter Pylori Gastritis

Role: lead

NCT06496087Not ApplicableCompleted

Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment

Role: lead

NCT06437210Not ApplicableCompleted

Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome

Role: lead

NCT06361992Phase 3Completed

Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

Role: lead

NCT06363201Not ApplicableNot Yet Recruiting

Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours

Role: lead

NCT03549273Phase 2Recruiting

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Role: lead

NCT03549494Phase 2Completed

Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction

Role: lead

NCT03559543Phase 2Completed

Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Role: lead

NCT05916911Phase 4Recruiting

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Role: lead

NCT05222841Phase 2Completed

The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility

Role: lead

NCT03717298Phase 2Completed

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Role: lead

NCT03562897Phase 2Completed

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Role: lead

NCT04980534Not ApplicableCompleted

Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip

Role: lead

NCT03541005Phase 3Completed

Evaluation of Obex® in Overweight and Obesity

Role: lead

NCT04701502Phase 2Completed

Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

Role: lead

NCT04407182Phase 2Completed

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

Role: lead

NCT04695951Phase 2Completed

Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract

Role: lead

NCT03540407Phase 2Completed

Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.

Role: lead

NCT03550482Phase 4Completed

Oncoxin® and Quality of Life in Cancer Patients

Role: lead